Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients

The hypoxia-hypoxia-inducible factor (HIF)-1α-A2-adenosinergic pathway protects tissues from inflammatory damage during antipathogen immune responses. The elimination of this physiological tissue-protecting mechanism by supplemental oxygenation may contribute to the high mortality of oxygen-ventilat...

Full description

Saved in:
Bibliographic Details
Published in:Physiology (Bethesda, Md.) Md.), 2022-01, Vol.37 (1), p.46-52
Main Authors: Halpin-Veszeleiova, Katarina, Hatfield, Stephen M
Format: Article
Language:English
Subjects:
COVID-19
Humans
Hypoxia
Neoplasms
Receptor, Adenosine A2A
Review
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The hypoxia-hypoxia-inducible factor (HIF)-1α-A2-adenosinergic pathway protects tissues from inflammatory damage during antipathogen immune responses. The elimination of this physiological tissue-protecting mechanism by supplemental oxygenation may contribute to the high mortality of oxygen-ventilated COVID-19 patients by exacerbating inflammatory lung damage. Restoration of this pathway with hypoxia-adenosinergic drugs may improve outcomes in these patients.
ISSN:1548-9213
1548-9221
DOI:10.1152/physiol.00010.2021